explore -WSS

explore

author：hotspot 2025-10-01 10:36:05 - browse：79

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The CDC's new social media misinformation war

hotspot

WSS

Obesity now affects over 1 billion people worldwide, study finds

340B reform proposal comes out of Senate working group

Congress gives doctors Medicare pay bump

How to fix the rural physician shortage in the U.S.

Pfizer highlights cancer drugs it thinks could reignite investor interest

A single Democrat is willing to weaken Medicare negotiation power

leisure time

explore

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Adopting new red light myopia treatments may be short

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why getting cancer drugs just got harder for rural patients

In age of alternative facts, a scholarly course on calling out crap

Top private equity targets in 2023: cardiology, clinical trials, lasers

Medical records are filled with copy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Moonlake's readout produced a cash windfall. Risks remain

FDA does about

explore

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Texas Medical Board asked to define abortion emergency exception

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Cano Health’s bankruptcy is a warning for Medicare Advantage

Devoted Health’s losses in Medicare Advantage persist

knowledge

hotspot

hotspot

hotspot